111 related articles for article (PubMed ID: 12023142)
1. Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Rao RD; Thomé SD; O'Fallon J; Earle JD; Dinapoli RP; Buckner JC
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):376-84. PubMed ID: 12023142
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Reid JM; Bagniewski PJ; Ames MM; Cascino TL; Marks RS
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):969-75. PubMed ID: 9869217
[TBL] [Abstract][Full Text] [Related]
4. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
[TBL] [Abstract][Full Text] [Related]
6. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Buckner JC; Schomberg PJ; McGinnis WL; Cascino TL; Scheithauer BW; O'Fallon JR; Morton RF; Kuross SA; Mailliard JA; Hatfield AK; Cole JT; Steen PD; Bernath AM
Cancer; 2001 Jul; 92(2):420-33. PubMed ID: 11466698
[TBL] [Abstract][Full Text] [Related]
7. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
8. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
Brem H; Ewend MG; Piantadosi S; Greenhoot J; Burger PC; Sisti M
J Neurooncol; 1995 Nov; 26(2):111-23. PubMed ID: 8787853
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Hochberg F; Prados M; Russell C; Weissman D; Evans R; Cook P; Burton G; Eisenberg PD; Valenzuela R; Verkh L
J Neurooncol; 1997 Mar; 32(1):45-55. PubMed ID: 9049862
[TBL] [Abstract][Full Text] [Related]
13. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.
Grossman SA; Wharam M; Sheidler V; Kleinberg L; Zeltzman M; Yue N; Piantadosi S
J Clin Oncol; 1997 Jul; 15(7):2596-603. PubMed ID: 9215830
[TBL] [Abstract][Full Text] [Related]
15. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
Salvati M; D'elia A; Frati A; Brogna C; Santoro A; Delfini R
J Neurosurg Sci; 2011 Mar; 55(1):1-6. PubMed ID: 21464805
[TBL] [Abstract][Full Text] [Related]
16. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Chang CH; Horton J; Schoenfeld D; Salazer O; Perez-Tamayo R; Kramer S; Weinstein A; Nelson JS; Tsukada Y
Cancer; 1983 Sep; 52(6):997-1007. PubMed ID: 6349785
[TBL] [Abstract][Full Text] [Related]
17. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Brandes AA; Scelzi E; Zampieri P; Rigon A; Rotilio A; Amista P; Berti F; Fiorentino MV
Am J Clin Oncol; 1997 Aug; 20(4):364-7. PubMed ID: 9256890
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Olivi A; Grossman SA; Tatter S; Barker F; Judy K; Olsen J; Bruce J; Hilt D; Fisher J; Piantadosi S;
J Clin Oncol; 2003 May; 21(9):1845-9. PubMed ID: 12721262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
